-
4 Things You Need to Know About Merck's Q4 Earnings Results
Post on 2/4/19
-
Pfizer's Next 3 Years: What Investors Can Expect
Post on 2/4/19
-
Outlook Therapeutics Closes Final Tranche of $20 Million Private Placement
Post on 2/1/19
-
AmerisourceBergen Corporation (ABC) CEO Steven Collins on Q1 2019 Results - Earnings Call Transcript
Post on 2/1/19
-
Cancer Genetics Announces Closing of Public Offering of Common Stock
Post on 1/31/19
-
Hitachi Chemical To Acquire apceth Biopharma GmbH
Post on 1/31/19
-
Pfizer: Strong Buy Heading Into 2019
Post on 1/31/19
-
3 Big Pharmas Expecting a Softer 2019
Post on 1/31/19
-
Trevena Announces $10M Stock Offering
Post on 1/30/19
-
Celgene: Long The Deal Spread
Post on 1/30/19
-
Pfizer Q4 Earnings Update: 4 Key Things You Need to Know
Post on 1/30/19
-
Better Buy: Johnson & Johnson vs. Pfizer
Post on 1/30/19
-
Cancer Genetics Announces Proposed Public Offering of Common Stock
Post on 1/28/19
-
For the Fifth Consecutive Year, Aramark Named a Top 50 Employer for People with Disabilities
Post on 1/28/19
-
BMS Reports Q4: Analysis Of Its Stock And Of Celgene
Post on 1/28/19
-
3 Things You Should Expect in Pfizer's Q4 Earnings Update
Post on 1/28/19
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Post on 1/27/19
-
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Post on 1/27/19
-
Covered-Call Writing With J&J
Post on 1/24/19
-
Johnson & Johnson: Goodbye Growth
Post on 1/24/19
-
Does Johnson & Johnson's Grim Outlook Spell Trouble for Big Pharma Stocks?
Post on 1/24/19
-
Johnson & Johnson (JNJ) Q4 2018 Earnings Conference Call Transcript
Post on 1/24/19
-
Better Buy: Amgen vs. Johnson & Johnson
Post on 1/24/19
-
PTC Therapeutics Announces Pricing of Public Offering of Common Stock
Post on 1/23/19
-
Talee Bio Announces $4.5 Million Award from the Cystic Fibrosis Foundation
Post on 1/23/19